Please login to the form below

Not currently logged in
Email:
Password:

CAR-Ts

This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

to administer therapy that doesn’t require the process of harvesting, modifying and re-infusing cells needed with autologous CAR-Ts. ... what some commentators think is a reason (alongside price and reimbursement) for sluggish uptake of

Latest news

  • Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

    There were signs of efficacy with AMG 420 even at a lower dose of 200µg/day, but the big question now is whether off-the-shelf drugs will match CAR-Ts ... treated in trials of Bluebird’s CAR-Ts had seven or more, with a might higher proportion of the

  • ASH18: CAR-T and drugs give new options for multiple myeloma ASH18: CAR-T and drugs give new options for multiple myeloma

    earlier timepoint, and Celgene is due to report results on no fewer than three anti-BCMA CAR-Ts developed by Juno – namely JCARH125, MCARH171 and FCARH143. ... five complete responses in five patients – that could pose a threat to the BCMA-targeting

  • Regeneron’s early stage bispecific shows promise Regeneron’s early stage bispecific shows promise

    Bispecifics and antibody drug conjugates will challenge CAR-Ts. The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave ... This approach could see them match the clinical

  • Celgene to launch five new products through to 2020 Celgene to launch five new products through to 2020

    myelofibrosis, thalassaemia therapy luspatercept, and CAR-T candidates lisocabtagene maraleucel (liso-cel) for lymphoma and bb2121 for multiple myeloma. ... The two CAR-Ts could be approved in 2020, while the other three candidates are due to be

  • Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

    Arie Belldegrun (left) and David Cheng . Belldegrun and Cheng they can go one better than these first generation autologous CAR-Ts. ... Allogene is among a number of companies who want to leapfrog the leaders with allogenic or 'off the shelf' CAR-Ts.

More from news
Approximately 8 fully matching, plus 15 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics